ImmunoGenes is a biopharmaceutical company specialized in the generation of transgenic animals for the production of polyclonal and monoclonal antibodies. Our unique approach to antibody production starts with a genetic modification that leads to the overexpression of the neonatal Fc receptor for IgG (FcRn). This receptor overexpression, in turn, results in a greater number and greater diversity of B cell clones and a strong immune response against weakly immunogenic targets. This creates an opportunity for pharmaceutical and biotech companies to use this technology in their development programs for therapeutics and diagnostics. Additionally, using such animals allows sufficient quantities of polyclonal antibodies to be harvested much faster than through standard techniques.
ImmunoGenes AG is incorporated in Zug, Switzerland. The Company was founded in 2008 and is the owner (100%) of its subsidiary ImmunoGenes Kft (Hungary), a 2007 spin-off from the Eötvös Loránd University, Budapest and Agricultural Biotechnology Center, Gödöllö.